Understanding the cell type–specific effects of STING activation has become increasingly important, especially because STING agonists are undergoing clinical testing as adjuvants to prime the immune system during checkpoint blockade for cancer therapy (190, 191, 192). This evidence concerns the gene STING1 and cancer.